| Model Number |
PED2-500-18 |
| Medical Device Problem Codes |
Device Dislodged or Dislocated (2923); Adverse Event Without Identified Device or Use Problem (2993); Unintended Movement (3026); Migration (4003)
|
| Health Effect - Clinical Codes |
Aneurysm (1708); No Clinical Signs, Symptoms or Conditions (4582); Clinical Endoleak (4843)
|
|
Type of Reportable Event
|
Malfunction
|
|
Event or Problem Description
|
|
Medtronic received a report that the device was successfully working after the surgery.The stent displacement was identified by the doctor a year later during a follow up evaluation.There was migration after deployment.The cause of the migration is unknown.The pipeline was implanted at the intended location.Full wall apposition was achieved.The pipeline was used for an approved (on-label) indication.The device and any accessories were prepared as indicated in the ifu.No patient symptoms or further complications were reported as a result of this event.There was no medical or surgical intervention needed to prevent a permanent impairment of a function.The event did not lead to or extend patient hospitalization.There was no injury as a result of the event.After the surgical processes, the angiographic results (xpercity evaluation) were favorable.The adverse results were identified on the follow up evaluation.The patient was undergoing surgery for treatment of an unruptured left internal carotid artery (ica) aneurysm.It was noted the patient's vessel tortuosity was normal.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information received reported that the physician mentioned the event occurred after the dsa fu at 1year.They did not specified a date: dsa fu were performed between (b)(6) 2024 /(b)(6) 2025.The morphology of each aneurysm was unknown at the time of the report.B285302- shield- jmf ¿ endoleak not resolved.Rt petrous cavernous aneurysm still filling with flow restriction that was not seen on the day of the implant.
|
| |
|
Event or Problem Description
|
|
Medtronic received a report that the device was successfully working after the surgery.The stent displacement was identified by the doctor a year later during a follow up evaluation.There was migration after deployment.The cause of the migration is unknown.The pipeline was implanted at the intended location.Full wall apposition was achieved.The pipeline was used for an approved (on-label) indication.The device and any accessories were prepared as indicated in the ifu.No patient symptoms or further complications were reported as a result of this event.There was no medical or surgical intervention needed to prevent a permanent impairment of a function.The event did not lead to or extend patient hospitalization.There was no injury as a result of the event.After the surgical processes, the angiographic results were favorable.The adverse results were identified on the follow up evaluation.The patient was undergoing surgery for treatment of an unruptured left internal carotid artery (ica) aneurysm.It was noted the patient's vessel tortuosity was normal.Additional information received reported that the physician mentioned the event occurred after the dsa fu at 1 year.They did not specified a date: dsa fu were performed between december2024 /january 2025.The morphology of each aneurysm was unknown at the time of the report.(b)(4)- shield ¿ endoleak not resolved.Rt petrous cavernous aneurysm still filling with flow restriction that was not seen on the day of the implant.
|
| |
|
Additional Manufacturer Narrative
|
|
H6 coding corrected based on all available information.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Medtronic received a report that the device was successfully working after the surgery.The stent displacement was identified by the doctor a year later during a follow up evaluation.There was migration after deployment.The cause of the migration is unknown.The pipeline was implanted at the intended location.Full wall apposition was achieved.The pipeline was used for an approved (on-label) indication.The device and any accessories were prepared as indicated in the ifu.No patient symptoms or further complications were reported as a result of this event.There was no medical or surgical intervention needed to prevent a permanent impairment of a function.The event did not lead to or extend patient hospitalization.There was no injury as a result of the event.After the surgical processes, the angiographic results (xpercity evaluation) were favorable.The adverse results were identified on the follow up evaluation.The patient was undergoing surgery for treatment of an unruptured left internal carotid artery (ica) aneurysm.It was noted the patient's vessel tortuosity was normal.Additional information received reported that the physician mentioned the event occurred after the dsa fu at 1year.They did not specified a date: dsa fu were performed between december2024 /january 2025.The morphology of each aneurysm was unknown at the time of the report.B285302- shield- jmf ¿ endoleak not resolved.Rt petrous cavernous aneurysm still filling with flow restriction that was not seen on the day of the implant.
|
| |
|
Additional Manufacturer Narrative
|
|
D4.Device information updated/correct based on all available information.H6.Patient coding updated based on available information.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received stating that the cause of the pipeline migration was not determined.The doctor believed the pipeline didn't do the work.Vessel tortuosity was moderate.Aneurysm was located in the right petrous cavernous segment.The doctor does not plan on performing any intervention and no more information was provided regarding if any other procedure was done.The information is confirmed by the physician.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|